PDPolina A. Danchenko

Polina A. Danchenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Polina A. Danchenko has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment of obstructive hypertrophic cardiomyopathy: the role of modern imaging and the place of surgery in the era of myosin inhibitors

    by M. O. Tregubova, K. V. Rudenko, M. M. Tkachenko, P. A. Danchenko, A. O. Bei

    Aim. To evaluate modern approaches to preoperative planning of septal myectomy in patients with obstructive hypertrophic cardiomyopathy (HCM), to define the role of multimodality imaging (echocardiography, magnetic resonance imaging (MRI), computed tomography (CT)) and the place of surgical treatment in the era of rapid development and clinical implementation of selective myosin inhibitors. Materials and methods. An analytical review of current clinical guidelines, results of major clinical trials on myosin inhibitors, and fundamental publications on the principles of radiological planning and surgical techniques in obstructive HCM was performed. A literature search was conducted in PubMed, Scopus, and Google Scholar databases with the following keywords: hypertrophic cardiomyopathy, septal myectomy, preoperative planning, cardiac CT, cardiac MRI, myosin inhibitors. Results. Modern multimodality imaging represents an essential stage of preoperative assessment, providing the surgeon with the ability to optimally plan the extent of resection, minimize cardiopulmonary bypass time, and significantly reduce postoperative complications. Although myosin inhibitors demonstrate a marked reduction in left ventricular outflow tract gradients and improvement in clinical status – the complex morphological nature of obstruction, involving papillary muscles, subvalvular structures of the mitral valve, and systolic anterior motion of the anterior leaflet of the mitral valve – often limits the possibility of complete correction by medical therapy alone. Conclusions. Septal myectomy, when performed in highly specialized expert centers, remains the gold standard for patients with symptomatic obstructive HCM refractory to optimal medical therapy. The success and safety of this intervention are directly correlated with the precision and detail of preoperative planning, based on the modern cardiac imaging arsenal.

  • Three Decades of the European Association for Cardio-Thoracic Surgery (EACTS) Residents’ Committee

    by Andrea Amabile, Nabil Hussein, Edoardo Zancanaro, Polina Danchenko, Felix Nägele, Soi Avgeridou, Gowthanan Santhirakumaran, Francesca Gatta, Beatrice Trabalza Marinucci, Jules Olsthoorn, et al.

    The European Association for Cardio-Thoracic Surgery (EACTS) Residents’ Committee (RC), established in 1996, has become a key driver of trainee representation and innovation in cardiothoracic surgery. Created to address heterogeneity in training across Europe, the RC has helped shape educational standards, promoted resident involvement in governance, and advanced academic development. Through surveys, targeted educational initiatives, and dedicated publication platforms, the Committee has identified persistent challenges while fostering collaboration and scholarship among trainees. Its recent expansion into digital education and global partnerships reflects an evolving role in a rapidly changing field. This Editorial provides an historical overview and highlights the efforts of the RC in training standardization, inclusivity, and international collaboration.

  • Open Access

    Multidisciplinary management of patients with hypertrophic cardiomyopathy

    by K. V. Rudenko, P. A. Danchenko, M. I. Rzhanyi, O. O. Chyzhevska, A. O. Bei, O. M. Kovalyova

    The article presents a review of literary and scientific sources from the MEDLINE database on PubMed, Web of Science, Scopus, and Google Scholar platforms, focusing on hypertrophic cardiomyopathy and its treatment aspects. In accordance with the recommendations of leading experts, a modern definition of hypertrophic cardiomyopathy is shown with a description of the classification of structural and functional cardiac abnormalities, associated symptoms, and generalized risk factors for sudden cardiac death in patients. A ranking of patients related to the left ventricular outflow tract obstruction and clinical manifestations is submitted. Based on international guidelines, the main principles for treating patients are given, depending on hemodynamic and clinical characteristics, including pharmacotherapy and invasive methods. Pathophysiological reasoning and clinical justification for prescribing drugs to correct complications are provided. The use of septal myectomy and alcohol septal ablation to correct morphological cardiac abnormalities and improve the clinical status of patients is outlined in a historical context. The results of one’s own experience in surgical treatment of patients with hypertrophic cardiomyopathy are presented.


  • Open Access

    Prediction of significant left ventricular myocardial fibrosis in patients with hypertrophic cardiomyopathy based on maximum wall thickness assessed by multiparametric cardiac MRI

    by M. S. Ishchenko, K. V. Rudenko, O. R. Romaniuk, S. R. Lutsiv, P. A. Danchenko

    Hypertrophic cardiomyopathy (HCM) is the most common cardiomyopathy, characterized by left ventricular (LV) hypertrophy and associated with an increased risk of sudden cardiac death (SCD). One of the key morphological predictors of SCD is myocardial fibrosis, which is visualized on cardiac magnetic resonance (CMR) imaging using late gadolinium enhancement (LGE). An LGE extent of ≥15 % of LV mass significantly increases the risk of ventricular arrhythmias and SCD. A potential parameter for predicting this is the maximum LV wall thickness, which may correlate with the extent of myocardial fibrosis. However, this association remains a subject of scientific investigation, and it is the main focus of this study. Aim. To assess the relationship and degree of correlation between maximum LV wall thickness and the presence of extensive myocardial fibrosis (LGE ≥15 %) detected by multiparametric CMR in patients with HCM. Materials and methods. Data from 207 patients with confirmed HCM who underwent multiparametric CMR at the National M. Amosov Institute of Cardiovascular Surgery affiliated to National Academy of Medical Sciences of Ukraine between January and December 2024 were analyzed. Radiologists performed LV myocardial segmentation and quantified fibrosis, reporting LGE as a percentage of total LV mass. Patients were divided into two groups according to the degree of fibrosis: Group I – patients without extensive fibrosis (LGE 15 %) was detected in 35 patients (16.9 %), whereas 172 patients (83.1 %) had absent, mild, or moderate fibrosis. Patients with extensive fibrosis (Group II) had significantly greater maximum wall thickness (29.8 ± 5.5 mm) compared to Group I (23.2 ± 4.8 mm, p < 0.001). ROC curve analysis identified an optimal cutoff value of maximum LV wall thickness of 26 mm to detect extensive fibrosis, with a sensitivity of 83 %, specificity of 69 %, and an AUC of 0.823. Conclusions. This study demonstrates a statistically significant correlation between maximum LV wall thickness and the presence of extensive myocardial fibrosis (LGE ≥15 %) in patients with HCM. This finding could be useful for assessing SCD risk when CMR is unavailable.

  • Contemporary surgical treatment of hypertrophic obstructive cardiomyopathy: insights from the Ukrainian National Referral Center

    by Polina Danchenko, Kostiantyn Rudenko, Maksym Rzhanyi, Liliana Hrubiak, Mykhailo Ishchenko, Mykhailo Kozhanov

    Purpose Hypertrophic obstructive cardiomyopathy (HOCM) remains a prevalent and clinically significant condition with a global prevalence of 1:200 to 1:500. In Ukraine, the estimated burden is approximately 75,000 patients, although national data remain limited. Since 2016, the Amosov National Institute of Cardiovascular Surgery in Kyiv has been a leading center for HOCM surgery, primarily performing septal myectomy (SM) with concomitant mitral valve (MV) repair. This review summarizes the evolution of the Institute’s surgical program, outcomes, and challenges faced under extraordinary circumstances. Methods Institutional experience with SM and MV repair between 2016 and 2025 was reviewed. Preoperative evaluation included transthoracic echocardiography (TTE), cardiac magnetic resonance (CMR) imaging, and/or computed tomography (CT). A refined transaortic SM technique was applied to optimize septal resection, relieve left ventricular outflow tract (LVOT) obstruction, and address dynamic mitral regurgitation (MR). Results SM consistently reduced LVOT gradients and eliminated MR in the majority of patients. In-hospital mortality remained below 1%, with a low incidence of major complications directly attributable to myectomy. Despite significant external pressures, including the coronavirus disease 2019 (COVID-19) pandemic and the ongoing full-scale war in Ukraine, surgical activity continued without interruption. Innovations in operative techniques and perioperative management further enhanced safety and outcomes. Conclusion The Amosov Institute has established a high-performing national program for HOCM surgery, demonstrating durable results despite unprecedented challenges. Ongoing refinement of minimally invasive strategies and strengthened international collaboration remain essential to address the global shortage of experienced myectomy surgeons and ensure wider access to advanced surgical care.


  • Open Access

    The role of cardiac MRI in risk stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy

    by M. S. Ishchenko, K. V. Rudenko, V. V. Lazoryshynets, Yu. I. Vitkovskyi, M. O. Tregubova, P. A. Danchenko

    Hypertrophic cardiomyopathy (HCM) is a prevalent genetic heart disease with a worldwide prevalence. Its estimated incidence in young individuals is approximately 1 case per 500 population. HCM in adults can be clinically diagnosed through visualization, either via 2D echocardiography or cardiac magnetic resonance (CMR) imaging, where the maximum thickness of any left ventricular (LV) segment, measured in end-diastolic phase, is 15 mm in the absence of other hypertrophy causes. Aim. To demonstrate the role and diagnostic capabilities of CMR as a powerful diagnostic tool for detecting and evaluating sudden cardiac death (SCD) risk factors in patients with HCM. Materials and methods. From January 2022 to September 2023, 236 CMR examinations were conducted and analyzed at the Diagnostic Radiology Department of Amosov National Institute of Cardiovascular Surgery in patients with suspected HCM. All examinations were performed on a magnetic resonance tomograph “Toshiba Vantage Titan 1.5T” until May 2023, and “Canon Vantage Orian 1.5T” from May to September 2023, with ECG and respiratory synchronization as well as intravenous injection of gadolinium-based contrast agent (Gadovist 1.0) at a dose of 0.1 mL/kg body weight. Statistical and mathematical data processing was performed by using the Statistica 6.0 (StatSoft Inc., USA) application package. Results. The mean age of the examined patients was 41 ± 28 years, there were 142 male (60 %) and 94 (40 %) female patients. Symmetric non-obstructive HCM was identified in 39 patients (16.5 %) and 184 patients (78.0 %) had asymmetric obstructive HCM. Apical HCM was diagnosed in 4 patients (1.5 %), and midventricular HCM – in 9 patients (4.0 %) including one patient with a combination of midventricular and apical forms. Risk factors for SCD were identified in 60 patients (25.4 %) with myocardial thickness exceeding 30 mm, 8 patients (3.3 %) with apical aneurysm, 4 patients (1.6 %) with reduced LV systolic function (LV ejection fraction <50 %), and 164 patients (69.4 %) with pathological late gadolinium enhancement. Conclusions. CMR is a modern, high-precision and powerful diagnostic method that plays a key role in identifying and assessing SCD risk factors in patients with HCM. CMR helps to identify HCM patients at high SCD risk who may benefit from preventive measures such as implantable cardioverter-defibrillator therapy.


  • Open Access

    Perioperative care in infective endocarditis

    by Eduard Quintana, Sara Ranchordas, Cristina Ibáñez, Polina Danchenko, Francis Edwin Smit, Carlos - Alberto Mestres

    Patients undergoing surgery for acute infective endocarditis are among those with the highest risk. Their preoperative condition has significant impact on outcomes. There are specific issues related with the preoperative situation, intraoperative findings, and postoperative management. In this narrative review, focus is placed on the most critical aspects in the perioperative period including the management and weaning from mechanical ventilation, the management of vasoplegia, the management of the chest open, antithrombotic therapy, transfusion, coagulopathy, management of atrial fibrillation, the duration of antibiotic therapy, and pacemaker implantation.


  • Open Access

    Fabry Disease, a Rare Disorder with Cardiac Manifestations. The Problem of Diagnosis and Treatment: a Literature Review

    by Kostiantyn V. Rudenko, Lidiia O. Nevmerzhytska, Olha M. Unitska, Polina A. Danchenko, Nadiia S. Leiko

    Fabry disease (FD) is an X-linked lysosomal storage disease caused by a mutation in the gene encoding α-galactosidase A and leads to reduced activity or complete absence of this enzyme, which causes the accumulation of globotriaosylceramide (Gb3) and its deacylated form (lyso-Gb3) in cells of the whole body. FD can occur both with multisystem manifestations, including damage to the nervous system, kidneys, and skin, and can affect only the heart. Cardiac involvement is a major cause of poor quality of life and death in patients with FD and an underrecognized cause of heart failure with preserved ejection fraction and ventricular arrhythmias in men over 30 years of age and women over 40 years of age. Cardiac damage begins at an early age, progresses subclinically until the appearance of significant symptoms, and usually manifests as leftventricular hypertrophy, mimicking hypertrophic cardiomyopathy. After the introduction of enzyme replacement therapy, early recognition of FD and differential diagnosis with other causes of leftventricular hypertrophy have become crucial to limit the progression of the disease. Recent advances in the understanding of cardiac pathophysiology and imaging have improved diagnostic and therapeutic approaches to the cardiac manifestations of this pathology. Modern achievements in the study of cardiac manifestations of FD have made it possible to significantly improve diagnostic and therapeutic approaches, in particular, in relation to the identification of pathogenetic mechanisms of organ damage and early disruption of their function. A better understanding of secondary pathogenic pathways, such as myocardial inflammation, may influence future therapeutic strategies and timely diagnosis of FD. Delay in diagnosis and untimely initiation of treatment remain critical problems for many patients with FD, especially for patients with late-onset cardiovascular manifestations, in whom treatment effects may be more limited and ineffective. Cooperation between specialists in genetic diseases and cardiologists remains important to identify patients before the appearance of cardiac symptoms in order to obtain maximum therapeutic effects.